National and Kapodistrian University of Athens
Development and in vitro/ in vivo evaluation of nasal films as nose-to-brain delivery systems in neurodegenerative diseases
Abstract
dc:descriptionThe main challenge for orally administered drugs in the treatment of neurodegenerative diseases is to cross the tightly packed structure of the blood-brain-barrier (BBB). Small, lipophilic drugs can cross the BBB; however, their potential binding with serum proteins and/or the first-pass metabolism effect significantly reduces the amount of active substance that reaches the brain. Consequently, the oral route of administration for the treatment of central nervous system (CNS) disorders requires reconciliation of the physicochemical properties of drugs with the tight regulation of their movement through the BBB. The nasal route offers a feasible alternative to oral and/or parenteral administration. It provides a non-invasive route to achieve nose-to-brain (NTB) delivery involving the olfactory and trigeminal nerves, as well as facilitating local or systemic drug action. Conventional liquid nasal dosage forms have failed to achieve adequate drug deposition on the olfactory epithelium being more applicable in topical delivery. Furthermore, possible leakage from the nostril or the ingestion of the administered liquid cause dose variability and gastrointestinal side effects, respectively. Moreover, stability issues of the liquid forms and their rapid clearance from nasal mucosa redirected scientists’ attention to solid dosage forms. More specifically, nasal powders permit the administration of larger doses, that can adhere to and remain on the nasal mucosa for a prolonged time. A versatile dosage form used for various routes of administration, including buccal, ophthalmic, vaginal, and transdermal, is the polymer film. Contact lenses have been proven effective devices to sustain the release of ophthalmic drugs, overcoming the limitations of eye drops, such as the rapid removal from the precorneal cavity due to the tear flow and the nasolacrimal drainage. Since similar limitations should be surpassed in the nasal delivery, the development of circular polymer films with dimensions tailored to those of the olfactory region could extend the residence time in the nasal cavity and enhance the absorption of the film-formulated drugs. Recently, an osmotic nasal polymeric film, as well as an insulin fast dissolving film were developed for topical action in the early-stage COVID-19 positive symptomatic patients and for the treatment of anosmia, respectively. However, no reports are found on nasal films for systemic and/or NBD delivery. The main objective and novelty of this PhD thesis involve the development and optimization of innovative polymer films for potential ΝΤΒ drug delivery. The aim is to introduce a new pharmaceutical dosage form for nasal delivery in the treatment of neurodegenerative diseases, such as Alzheimer’s disease (AD) and Multiple Sclerosis (MS), incorporating critical aspects of nasal powders, such as mucosal adhesion and stability. In this context, nasal films were developed using the Design of Experiments methodology (DoE). Two Active Pharmaceutical Ingredients (APIs) were selected: the lipophilic but with good solubility Donepezil hydrochloride (DH) for the treatment of AD and the lipophilic, low-solubility fingolimod hydrochloride (FH) for the treatment of MS. Nasal films were characterized in vitro and ex vivo and the application of experimental design allowed for determining the effects and possible interactions of the selected factors on the dependent variables (responses). The serum and brain pharmacokinetics (PKs) of the optimized formulations were further studied after intranasal (IN) administration in mice in comparison to the oral route. Based on the dual activity of DH as an Acetylcholinesterase Inhibitor (AChEI) and a Sigma-1 receptors (Sig-1R) agonist, the second objective of this PhD thesis focuses on the concept of drug repurposing. Specifically, the possible use of DH in the treatment of the Krabbe disease (KD) was explored. KD is a demyelinating disorder caused by mutations in the galactocerebrosidase (GALC) gene, affecting mostly children in the 3rd and 6th month of their life, resulting in toxic accumulation of psychosine. The severity of the disease leads to progressive damage of the central and peripheral nervous system, and patients do not survive after the age of 2 years. The presentation of the study results is structured into four Parts (A-D). In the first part, “Part A: Introduction & Study design”, the rational of the study and a description of the study protocols and methodology is given together with the study aim and objectives, “Chapter 1: Introduction” and “Chapter 2: Study design and Methodology”. In “Chapter 1: Introduction”, a review on nasal drug deliver is given and the most recent information on Alzheimer’s disease, Multiple sclerosis and Krabbe’s disease are discussed. In, “Chapter 2: Study design and Methodology” an overview of the study design and the basic theoretical aspects of the methodologies applied for the study is given. Furthermore, each chapter of parts “B-D" of the present thesis contains specific information about the experimental procedures and equipment used, to allow the independent comprehension of their application at each stage of the study. In brief, in Chapter 2 the following methodologies used in this thesis are described: Physicochemical evaluation of film pharmaceutical dosage forms: Thickness, weight, folding endurance, mucoadhesive ability, swelling, stability, content uniformity, % moisture loss, in vitro drug release, ex vivo drug permeation. Design of Experiments Principles: Quality of pharmaceutical forms, Quality by Design, factorial designs, central composite designs. Non-compartmental Pharmacokinetic Analysis. Animal studies: Pharmacokinetic studies. Drug repurposing in demyelinating diseases: process steps Statistical data analysis was performed by SPSS version 26.0 (IBM SPSS Statistics for Windows, Version 26.0, IBM Corporation, Armonk, NY, USA) or GraphPad Prism 8.0 (GraphPad Software) software packages. Design-Expert® Software, v.11 (Stat-Ease, Inc., Minneapolis, MN, USA) was utilized to construct and analyze the design space, employing Analysis of Variance (ANOVA) to assess the selected model and its individual terms, while Phoenix® version 8.3 PK/PD software package (Certara, Princeton, NJ, USA) was used for the NCA of the PK data. The second, third, and fourth parts of the study presentation (Parts B, C & D) are structured into chapters and each chapter is organized to be read independently. More specifically: “Part B: Development and Nose-to-Brain delivery of donepezil nasal film for Alzheimer’s disease in C57BL/6J mice”, consists of three chapters. The first one describes the development and in vitro/ex vivo evaluation of polymeric donepezil nasal film for potential use in AD, using experimental design (Chapter 3). The second covers the assessment of a novel IN administration technique for NTB delivery of biodegradable nasal films to C57BL/6 mice (Chapter 4). Lastly, Chapter 5 presents the determination of the donepezil PK parameters after the administration of the developed nasal films in C57BL/6J mice, in comparison to the oral solution. The chapters are structured as follows: Chapter 3: Development and in vitro-ex vivo evaluation of novel polymeric nasal donepezil films for potential use in Alzheimer’s disease using experimental design. The objective and novelty of the present study are the development and optimization of innovative nasal film of DH for potential use in AD. Hydroxypropyl methylcellulose (HPMC) E50 (factor A) nasal films, with Polyethylene glycol (PEG) 400 as plasticizer (factor B), and Methyl-β-Cyclodextrin (Me-β-CD), as a permeation enhancer (factor C), were prepared and characterized in vitro and ex vivo. An experimental design was used to determine the effects of the selected factors on permeation profile of DH through rabbit nasal mucosa (response 1) and on film flexibility/foldability (response 2). A face-centered central composite design with three levels was applied, and 17 experiments were performed in triplicate. The prepared films exhibited good uniformity of DH content (90.0 ± 1.6%–99.8 ± 4.9%) and thickness (19.6 ± 1.9–170.8 ± 11.5 μm), storage stability characteristics, and % residual humidity (<3%), as well as favorable swelling and mucoadhesive properties. Response surface methodology determined the optimum composition for flexible nasal film with maximized DH permeation. All selected factors interacted with each other, and the effect of these interactions on responses is strongly related to the factor’s concentration ratios. Based on these encouraging results, in vivo serum and brain PK study of the optimized nasal film in comparison to DH oral administration, was performed in an animal model. Chapter 4: Intranasal Administration of a Polymeric Biodegradable Film to C57BL/6 MiceNasal drug delivery in rodents is a challenging procedure, especially for brain targeting, as the position of the material in the nasal cavity determines the success of the administration method. The objective of this study was to assess a novel IN administration technique for NTB delivery of biodegradable nasal films. The method was performed in C57BL/6 mice (n = 10; age, 8 weeks) under inhaled sevoflurane anesthesia. Twenty-four-gauge (24G) catheters were used for the procedure. An HPMC-based film was formed in the lumen of the catheter and then delivered into the mouse nostril by pushing it out of the lumen, using a trimmed and polished needle. Methylene blue was incorporated in the film-forming gel to indicate the delivery area in which the films were deposited. After administration, all mice recovered from anesthesia without incident. None of the mice showed any signs of injury, discomfort, or nose bleeding, thus allowing us to characterize the administration method as noninvasive. Furthermore, postmortem evaluation revealed olfactory-centered placement of the polymeric films, confirming the accuracy and repeatability of the method. In conclusion, this study documented the use of a novel, noninvasive, IN administration technique for NTB drug delivery of biodegradable films for use in mice. Chapter 5: Nose-to-Brain delivery of donepezil after the administration of HPMC-Me-β-CD-PEG400 based nasal films, in C57BL/6J miceNasal administration has been demonstrated as an effective alternative for drug delivery to CNS, especially for use in neurodegenerative diseases. DH is a widely used AChEI for the management of AD, able to cross the BBB after oral administration. However, DH undergoes extensive first-pass metabolism, a fact that limits the amount of drug reaching the CNS. The purpose of the present study was the in vivo NTB delivery of DH, formulated in the recently developed HPMC-Me-β-CD-PEG400 based polymeric nasal film. In particular, a PK study was carried out in comparison with oral (per os) administration of DH solution. Sparse sampling NCA was applied of all in vivo data to determine the PK parameters. The PK profiles after IN and per os administration revealed the pre-eminence of the nasal film in DH delivery, both to the CNS and bloodstream, resulting in Cmax values 5.7 and 3.9 times as higher, respectively at each site. The effectiveness of nasal film is also witnessed by AUC values, as well as Drug Targeting Efficiency Percentage and nose-to-brain Direct Transport Percentage, respectively, found equal to 212% and 53%. “Part C: Application of nasal film form in highly lipophilic molecules: The example of fingolimod” consists of one chapter describing the application of the polymeric nasal film technology for NTB delivery of a highly lipophilic molecule, namely fingolimod hydrochloride (FH), a sphingosine-1-phosphate receptor modulator that acts on lymphocytes. Additionally, drug’s kinetics after IN administration to C57BL/6J mice were explored and reported in this chapter (Chapter 6), as follows: Chapter 6: Development and Nose-to-Brain delivery of fingolimod HPMC- based nasal films in C57BL/6J miceFingolimod hydrochloride, also known by the trade name Gilenya®, is a medication approved for the treatment of MS. Although it is characterized by efficient absorption and has a 93% oral bioavailability, its oral absorption is notably slow, with a Tmax of 8 to 12 h after administration. Additionally, it undergoes extensive hepatic metabolism. In light of this, IN administration serves as an alternative that ensures efficient NTB and systemic delivery, reducing peripheral organ exposure, bypassing the first pass effect, and significantly enhancing the available dose fraction at the target site. The preclinical data available in literature is limited, with existing studies lacking a detailed description of the experimental protocol, particularly regarding the exact administration method and tissue collection procedures. In this context, the formulation of FH as a nasal film emerged as a promising approach for achieving more efficient brain targeting, circumventing the impact of first-pass hepatic metabolism, and potentially accelerating the attainment of steady state (SS) concentrations in brain and serum. For this purpose, the developed technology of donepezil nasal film, as described in Chapter 3, was implemented. DoE was applied, involving the same factors/components [HPMC E50 as polymer (factor A), PEG 400 as plasticizer (factor B), and Me-β-CD, as permeation enhancer (factor C)] at both low and high levels. The resulting films underwent in vitro and ex vivo characterization. Two possible syntheses of FH nasal film were selected based on their in vitro and ex vivo performance for further in vivo evaluation. These are formulation F3, containing only 3% w/w HPMC E50, and formulation F4, which incorporates an additional 6% of Me-β-CD in its composition. A comparative PK study was performed using these two syntheses of FH nasal film and the oral FH solution, for IN and per os (PO) administration, respectively, in C57BL/6J mice. The brain and serum distribution PKS of the drug were studied, applying the sparse sampling NCA. The application of FH nasal film technology to the nasal cavity demonstrated efficient and rapid delivery of the drug to both serum and brain, resulting in higher drug levels compared to oral delivery. Considering the first 6 h after both oral and IN administration, nasal films effectively enhanced the relative bioavailability of FH in the brain and serum, despite using a dose 2.5 times lower than the oral one. The presence of Me-β-CD in the film’s synthesis did not affect the extent of exposure in either bloodstream or brain. However, it can be hypothesized that it delays the absorption in both cases, resulting in a higher Tmax in the serum and controlled drug release in the brain. Overall, achieving Cmax within the first 30 min after nasal film administration as opposed to the longer time required for the oral solution, underscores the potential clinical application of a combined IN and oral treatment once a day, which could expedite reaching the steady state concentration (CSS).“Part D: Drug repurposing: The effect of donepezil hydrochloride in Twitcher’s mouse model for Krabbe’s disease” consists of one chapter describing the effect of DH on myelin state regulation in the context of drug repurposing, and its potential use as therapeutic candidate for demyelinating diseases such as KD, as follows: Chapter 7: Donepezil effect on demyelination in a mouse model of Krabbe’s Disease Krabbe disease is a demyelinating disorder caused by mutations in the GALC gene, resulting in toxic accumulation of psychosine. In parallel, AD is a neurodegenerative disorder characterized by cognitive decline due to the formation of neurofibrillary tangles and plaques in the brain. Current therapeutic strategies for AD target the accumulation of amyloid-beta and tau hyperphosphorylation, as well as neuroinflammation and glial cell hypertrophy. However, myelin aberrations, which are associated with AD, have also been identified as early events in the disease progression. AChEIs are commonly used for symptomatic management of AD and are suggested to have potential disease-modifying effects, including regulating myelin state. In particular, DH, an AChEI drug, promotes myelination and increases the expression of myelin-related genes. This drug also acts as an agonist for Sig-1R, which are implicated in demyelination diseases. In the context of drug repurposing, here we demonstrate that administration of donepezil has protective effects in the twitcher mouse model of KD. We provide data showing that DH preserves myelin and reduces glial cell reactivity in the brains of twitcher mice. Moreover, DH also improves behavioral phenotypes and increases lifespan in twitcher animals. These findings suggest that donepezil, with its dual activity as an AChE inhibitor and Sig-1R agonist, may hold promise as a therapeutic candidate for demyelinating diseases, including KD. In conclusion, the present study revealed the following: Regarding the development and evaluation of polymeric nasal films:1.Biocompatible polymeric, HPMC-based, nasal films for DH delivery were developed. These films employed PEG 400 as a plasticizer agent and Me-β-CD as a permeation enhancer for the first-time. Their formulation characteristics and nasal mucosa permeability were tested in vitro and ex vivo, respectively.2.The application of face centered central composite design with three factors [HPMC E50 (factor A), PEG 400 (factor B), and Me-β-CD, (factor C)] at three levels identified the composition that ensures film flexibility and maximizes DH permeation across the nasal mucosa barrier.3.The comparative PK study of IN vs PO administration of DH was performed in C57BL/6J mice. The study demonstrated the applicability of nasal films for both NTB delivery and systemic absorption.3.Nasal films effectively increased the relative bioavailability of DH in the brain and serum, even with a 2.5 times lower dose.4. The application of nasal film technology to the lipophilic molecule FH, characterized by low solubility in the nasal cavity, exhibited efficient and rapid delivery of the drug to both serum and brain.5. Achieving Cmax within the first 30 min after nasal film administration, in contrast to the longer time required for oral solution, underscores the potential clinical application of a combined IN and oral treatment, once a day, to reach the CSS more quickly.6. From a future clinical perspective, the development of a single-dose IN film that ensures NTB delivery with dose consistency and repeatability could address issues of fluctuating therapy response due to leakage, sneezing, or variable spraying in existing nasal forms. In the context of drug repurposing, it is demonstrated that:-The administration of donepezil has protective effects in the twitcher mouse model of KD.-DH preserves myelin and reduces glial cell reactivity in the brains of twitcher mice.-DH improves behavioral phenotypes and increases lifespan in twitcher animals. -These findings suggest that DH, with its dual activity as an AChEI and Sig-1R agonist, holds promise as a therapeutic candidate for demyelinating diseases, including KD.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papakyriakopoulou, Paraskevi
- Παπακυριακοπούλου, Παρασκευή
Subjects
dc:subject × 32- Ρινικά φιλμ
- Ρινικά υμένια
- Ενδορινική χορήγηση
- Μεταφορά από τη μύτη στον εγκέφαλο
- Δονεπεζίλη
- Φινγκολιμόδη
- Πειραματικός σχεδιασμός
- Υδροξυπροπυλο μεθυλοκυτταρίνη
- β - κυκλοδεξτρίνη
- Πολυαιθυλενογλυκόλη
- Νόσος Αλτσχάιμερ (ΝΑ)
- Πολλαπλή σκλήρυνση
- Νόσος Κρεμπς
- Nasal films
- Intranasal administration
- Nose-to-brain delivery
- Intranasal delivery
- Donepezil
- Fingolimod
- Design of experiments
- Hydroxypropyl methylcellulose
- B-cyclodextrin
- Polyethylene glycol
- Alzheimer's disease
- Multiple sclerosis
- Krabbe's disease
- Επιστήμες Υγείας
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες υγείας, άλλοι τομείς
- Health Sciences
- Medical and Health Sciences
- Health sciences, miscellaneous
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54852